Cargando…

JNK at the crossroad of obesity, insulin resistance, and cell stress response

BACKGROUND: The cJun-N-terminal-kinase (JNK) plays a central role in the cell stress response, with outcomes ranging from cell death to cell proliferation and survival, depending on the specific context. JNK is also one of the most investigated signal transducers in obesity and insulin resistance, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Solinas, Giovanni, Becattini, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279903/
https://www.ncbi.nlm.nih.gov/pubmed/28180059
http://dx.doi.org/10.1016/j.molmet.2016.12.001
_version_ 1782502861551173632
author Solinas, Giovanni
Becattini, Barbara
author_facet Solinas, Giovanni
Becattini, Barbara
author_sort Solinas, Giovanni
collection PubMed
description BACKGROUND: The cJun-N-terminal-kinase (JNK) plays a central role in the cell stress response, with outcomes ranging from cell death to cell proliferation and survival, depending on the specific context. JNK is also one of the most investigated signal transducers in obesity and insulin resistance, and studies have identified new molecular mechanisms linking obesity and insulin resistance. Emerging evidence indicates that whereas JNK1 and JNK2 isoforms promote the development of obesity and insulin resistance, JNK3 activity protects from excessive adiposity. Furthermore, current evidence indicates that JNK activity within specific cell types may, in specific stages of disease progression, promote cell tolerance to the stress associated with obesity and type-2 diabetes. SCOPE OF REVIEW: This review provides an overview of the current literature on the role of JNK in the progression from obesity to insulin resistance, NAFLD, type-2 diabetes, and diabetes complications. MAJOR CONCLUSION: Whereas current evidence indicates that JNK1/2 inhibition may improve insulin sensitivity in obesity, the role of JNK in the progression from insulin resistance to diabetes, and its complications is largely unresolved. A better understanding of the role of JNK in the stress response to obesity and type-2 diabetes, and the development of isoform-specific inhibitors with specific tissue distribution will be necessary to exploit JNK as possible drug target for the treatment of type-2 diabetes.
format Online
Article
Text
id pubmed-5279903
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-52799032017-02-08 JNK at the crossroad of obesity, insulin resistance, and cell stress response Solinas, Giovanni Becattini, Barbara Mol Metab Review BACKGROUND: The cJun-N-terminal-kinase (JNK) plays a central role in the cell stress response, with outcomes ranging from cell death to cell proliferation and survival, depending on the specific context. JNK is also one of the most investigated signal transducers in obesity and insulin resistance, and studies have identified new molecular mechanisms linking obesity and insulin resistance. Emerging evidence indicates that whereas JNK1 and JNK2 isoforms promote the development of obesity and insulin resistance, JNK3 activity protects from excessive adiposity. Furthermore, current evidence indicates that JNK activity within specific cell types may, in specific stages of disease progression, promote cell tolerance to the stress associated with obesity and type-2 diabetes. SCOPE OF REVIEW: This review provides an overview of the current literature on the role of JNK in the progression from obesity to insulin resistance, NAFLD, type-2 diabetes, and diabetes complications. MAJOR CONCLUSION: Whereas current evidence indicates that JNK1/2 inhibition may improve insulin sensitivity in obesity, the role of JNK in the progression from insulin resistance to diabetes, and its complications is largely unresolved. A better understanding of the role of JNK in the stress response to obesity and type-2 diabetes, and the development of isoform-specific inhibitors with specific tissue distribution will be necessary to exploit JNK as possible drug target for the treatment of type-2 diabetes. Elsevier 2016-12-08 /pmc/articles/PMC5279903/ /pubmed/28180059 http://dx.doi.org/10.1016/j.molmet.2016.12.001 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Solinas, Giovanni
Becattini, Barbara
JNK at the crossroad of obesity, insulin resistance, and cell stress response
title JNK at the crossroad of obesity, insulin resistance, and cell stress response
title_full JNK at the crossroad of obesity, insulin resistance, and cell stress response
title_fullStr JNK at the crossroad of obesity, insulin resistance, and cell stress response
title_full_unstemmed JNK at the crossroad of obesity, insulin resistance, and cell stress response
title_short JNK at the crossroad of obesity, insulin resistance, and cell stress response
title_sort jnk at the crossroad of obesity, insulin resistance, and cell stress response
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279903/
https://www.ncbi.nlm.nih.gov/pubmed/28180059
http://dx.doi.org/10.1016/j.molmet.2016.12.001
work_keys_str_mv AT solinasgiovanni jnkatthecrossroadofobesityinsulinresistanceandcellstressresponse
AT becattinibarbara jnkatthecrossroadofobesityinsulinresistanceandcellstressresponse